Faculty mentor: Blair Armstrong
Drug-free macromolecular therapeutics (DFMTs) are an emerging form of therapeutics that seek to bridge the gap created by clinical drug resistance, specifically for Non-Hodgkin’s Lymphoma. DFMTs function by clustering surface cell receptors to elicit a cellular response. Here I evaluated the properties of four novel fusion proteins consisting of elastin-like polypeptides and alpha-helical peptides. Establishing these physicochemical properties allows for future optimization for therapeutic use.
Click below to hear me present my poster!
Questions or comments? Contact me at: email@example.com